Full-Time

Senior Salesforce Developer

Posted on 5/9/2026

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Pune, Maharashtra, India

In Person

Category
Engineering Management (1)
Required Skills
Salesforce
Data Governance
DevOps
Requirements
  • Bachelor’s degree in computer science or related field with 5+ years’ experience in Salesforce development, data & security area
  • Excellent problem-solving skills with attention to detail
  • High proficiency in enterprise scale data management systems and implementations
  • Ability to work in a highly dynamic and deadline driven environment
  • Needs to be a strong team player with excellent problem solving capabilities
  • Good organization and communications skills
  • Strong analytical thinking capabilities
  • Bachelor’s Degree in Computer Science, Information Technology or any other related discipline or equivalent related experience
  • 4+ years of directly-related or relevant experience, preferably in software designing and development
Responsibilities
  • Oversee the design, development, implementation, and maintenance of Salesforce CRM solutions to meet business objectives
  • Lead a team of administrators, developers, data and Security architects/leads in executing projects and initiatives related to Salesforce platform enhancements
  • Collaborate with cross-functional teams to gather requirements, define project scope, and ensure successful delivery of Salesforce projects
  • Provide strategic guidance on leveraging Salesforce features to streamline sales processes, improve customer service operations, and enhance user experience
  • Manage user access, security settings, data integrity, and system configurations within the Salesforce platform
  • Develop and maintain documentation related to system configurations, processes, workflows, and best practices
  • Conduct regular training sessions for end-users to promote adoption of new features and functionalities within the Salesforce CRM system
  • Stay current on emerging trends and best practices in the CRM space to recommend innovative solutions that align with business goals
  • Managing a dedicated team for both Data and Security, including architects and developers to build scalable and modular architecture, to be leveraged across multiple Salesforce Orgs at Cencora
  • Managing all Data and Security related aspects of the existing deployments while working towards standardizing the framework, by undertaking initiatives
  • Collaborating with cross-functional teams in areas such as Salesforce CRM implementation, business analytics and process improvement to ensure smooth operations
  • Working closely with DevOps teams to ensure all the new projects/deployments are compliant to the overall Data and Security framework
  • Monitoring the performance of existing solution and troubleshooting/mitigating any issues that arise due to evolving business/technology scenarios
  • Documenting technical specifications, processes, and best practices
  • Manage ongoing customer data projects to deliver accurate data to a variety of teams, systems and processes across the business
  • Managing and implementing tools/systems/processes needed to build and maintain robust data hygiene standards and overall data governance
  • Managing multiple Salesforce CRM projects in a fast-paced business environment, and prioritizing work efforts to ensure projects stay on track to hit deadlines
  • Building and maintaining positive working relationships with stakeholders and internal customers across the enterprise
  • Work to continually improve processes, efficiency, and quality
Desired Qualifications
  • Certified Salesforce Administrator (ADM201) is preferred
  • Experience in designing Salesforce Data structure and Security framework for large deployments involving multiple Salesforce products

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Simplify Jobs

Simplify's Take

What believers are saying

  • OneOncology $5B acquisition completed December 2025 boosts specialty oncology leadership.
  • EyeSouth retina business $1.1B deal expands Retina Consultants, accretive to EPS post-closure.
  • FY2026 EPS guidance raised to $17.65–$17.90 despite revenue headwinds from biosimilars.

What critics are saying

  • Frank R. Cruz investigation triggers shareholder lawsuits after May 6, 2026 Q2 revenue miss.
  • McKesson and Cardinal Health seize specialty drug share via aggressive GLP-1 pricing.
  • Inflation Reduction Act price cuts compress margins beyond $2B Q2 2026 headwind.

What makes Cencora unique

  • Cencora rebranded from AmerisourceBergen in August 2023, trading as COR on NYSE.
  • Cencora operates 1,400 locations across 50+ countries for global pharmaceutical distribution.
  • Cencora uniquely serves human and animal health with specialty pharmacy and MSO platforms.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.